Chika Madu MD, Named Chair of Radiation Oncology at Staten Island University Hospital

Chika Madu MD has been appointed chair of Radiation Oncology at Staten Island University Hospital (SIUH).

In this new role, Dr. Madu will oversee all radiation oncology clinical care, research, and training programs.

Chika Madu MD joined SIUH as an Attending Physician in Radiation Medicine in 2015. Throughout her career, Dr. Madu has demonstrated her commitment to excellent clinical care, focusing on patient safety and quality improvement.

Devoted to medical education and research, Dr. Madu sees research as one of cornerstones of cancer care. In collaboration with the Northwell Health Cancer Institute, SIUH is making research a major part of cancer care services.

“Dr. Madu is a national leader in the field of radiation,” said Brahim Ardolic, MD, executive director of SIUH. “Her expertise, experience, and leadership will help bring an already exceptional department to even greater heights in caring for our patients, advancing research, and training the next generation of clinicians and scientists.”

An important tool in cancer treatment, radiation medicine offers the most comprehensive range of radiation therapy treatment programs on Staten Island, treating most types of cancer, including brain, head and neck, lung, breast, intestinal, bladder and prostate, sarcomas and pediatric tumors.

Dr. Madu currently serves as Chair of the Cancer Committee at SIUH, Chair of the Quality Management Committee for Radiation Medicine at SIUH, system-wide Radiation Medicine representative for the Northwell Health Physician Partners Quality Committee, and is also a member of SIUH Women in Medicine Executive committee.

“As the health care environment continues to shift, we are confident Dr. Madu will greatly influence our ability to evolve with the ever-changing demands in medicine,” explains Dr. Ardolic. “We have no doubt that her unique skills, energy and vision will propel the department to new heights.”

Dr. Madu received her Medical Degree from the University of Michigan Medical School and completed her residency in Radiation Oncology at the University of Pennsylvania. Following her training,

Dr. Madu joined the faculty at the Lombardi Cancer Center at Georgetown University Hospital where she served as Residency Program Director in the Department of Radiation Medicine and Assistant Professor at the Georgetown University School of Medicine. She is currently an Assistant Professor of Radiation Medicine at the Zucker School of Medicine at Hofstra/ Northwell.

Nationally, Dr. Madu also holds a leadership position within the American Society for Radiation Oncology’s CHEDI committee, where she serves as Co-lead in the Advocacy Working Group, aimed at eliminating barriers to minority enrollment into clinical trials.

Expanded care close to home 

SIUH is currently building the new Florina Cancer Center in response to the increasing prevalence of the disease on Staten Island, and the desire to improve outcomes through leading transformations in cancer care delivery and accelerating translational research.

Dr. Madu has been one of the key contributors to the state-of-the-art design and technology of the Center. She looks forward to engaging her team in working together towards organizational goals and fostering multidisciplinary collaboration for the optimal treatment and outcomes for cancer patients in our community.

“As our Cancer Center looks forward to the future, we are committed to maintaining our accreditations, and to providing safe, effective, high quality cancer care to our patients and their families,” said Chika Madu MD.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”